Paper Search Console

Home Search Page About Contact

Journal Title

Title of Journal: PharmacoEconomics

Search In Journal Title:

Abbravation: PharmacoEconomics

Search In Journal Abbravation:

Publisher

Springer International Publishing

Search In Publisher:

DOI

10.1002/pro.121578

Search In DOI:

ISSN

1179-2027

Search In ISSN:
Search In Title Of Papers:

Resource Modelling The Missing Piece of the HTA J

Authors: Praveen Thokala Simon Dixon Beate Jahn
Publish Date: 2014/11/20
Volume: 33, Issue: 3, Pages: 193-203
PDF Link

Abstract

Within health technology assessment HTA costeffectiveness analysis and budget impact analyses have been broadly accepted as important components of decision making However whilst they address efficiency and affordability the issue of implementation and feasibility has been largely ignored HTA commonly takes place within a deliberative framework that captures issues of implementation and feasibility in a qualitative manner We argue that only through a formal quantitative assessment of resource constraints can these issues be fully addressed This paper argues the need for resource modelling to be considered explicitly in HTA First economic evaluation and budget impact models are described along with their limitations in evaluating feasibility Next resource modelling is defined and its usefulness is described along with examples of resource modelling from the literature Then the important issues that need to be considered when undertaking resource modelling are described before setting out recommendations for the use of resource modelling in HTAThe authors would like to acknowledge the feedback from the reviewers There are no conflicts of interest for any of the authors SD wrote the initial drafts for Sects 1 2 and 6 PT and BJ wrote the initial drafts for Sects 3 4 and 5 All authors contributed to the finalising the paper and revising the paper based on reviewers’ comments PT is the overall guarantor for the paper


Keywords:

References


.
Search In Abstract Of Papers:
Other Papers In This Journal:

  1. Análisis farmacoeconómico del tratamiento de la deficiencia de hierro con hierro carboximaltosa (Ferinject®) en España
  2. For a Step Change to Curb the Obesity Epidemic
  3. ESSENCE
  4. Coste-efectividad de dalteparina en la profilaxis y manejo de la enfermedad tromboembólica venosa (ETV) asociada al paciente adulto médico y quirúrgico en México
  5. Risperidone more cost effective than olanzapine in schizophrenia?
  6. Review of Models Used in Economic Analyses of New Oral Treatments for Type 2 Diabetes Mellitus
  7. ‘Viagra’ making headlines again in the UK
  8. Reform der Erstattungs- und Preisregulierung von verschreibungspflichtigen Arzneimitteln auf dem Markt der gesetzlichen Krankenversicherungen in Deutschland
  9. Calculating Total Health Service Utilisation and Costs from Routinely Collected Electronic Health Records Using the Example of Patients with Irritable Bowel Syndrome Before and After Their First Gastroenterology Appointment
  10. Trastuzumab for the Treatment of HER2-Positive Metastatic Gastric Cancer
  11. Cost Implications of Value-Based Pricing for Companion Diagnostic Tests in Precision Medicine
  12. I costi del dolore cronico/ricorrente in medicina generale
  13. The Problem of Embedded Decision Nodes in Cost-Effectiveness Decision Trees
  14. Análisis farmacoeconómico del tratamiento de las infecciones complicadas de piel y tejidos blandos con tigeciclina o la combinación de vancomicina y aztreonam en España
  15. Impacts of Health Insurance Benefit Design on Percutaneous Coronary Intervention Use and Inpatient Costs among Patients with Acute Myocardial Infarction in Shanghai, China
  16. Big Data and Its Role in Health Economics and Outcomes Research: A Collection of Perspectives on Data Sources, Measurement, and Analysis
  17. “Lost in Translation”
  18. Cost-Effectiveness Analysis of Pharmaceutical Treatment Options in the First-Line Management of Major Depressive Disorder in Belgium
  19. Moving from demand management to disease management
  20. Impiego di un’associazione fissa di formoterolo e budesonide nel trattamento del paziente asmatico

Search Result: